Billiontoone (NASDAQ:BLLN) Trading 7.7% Higher – Should You Buy?

Billiontoone, Inc. (NASDAQ:BLLN)’s share price traded up 7.7% during mid-day trading on Monday . The company traded as high as $88.35 and last traded at $88.9690. 299,183 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 383,568 shares. The stock had previously closed at $82.63.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BLLN. Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Wells Fargo & Company lowered their target price on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. BTIG Research lowered their target price on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Guggenheim lifted their target price on shares of Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $125.29.

Billiontoone Stock Performance

The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. The company’s 50 day simple moving average is $80.29. The stock has a market cap of $3.84 billion and a PE ratio of 151.60.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analyst estimates of $95.81 million. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. The business’s revenue for the quarter was up 83.8% on a year-over-year basis. As a group, sell-side analysts forecast that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Hedge Funds Weigh In On Billiontoone

Several large investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in shares of Billiontoone by 8,603.4% in the 1st quarter. Bank of America Corp DE now owns 12,707 shares of the company’s stock valued at $1,003,000 after purchasing an additional 12,561 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Billiontoone by 151.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company’s stock valued at $2,408,000 after purchasing an additional 18,389 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Billiontoone in the 1st quarter valued at $4,046,000. Public Employees Retirement System of Ohio acquired a new position in shares of Billiontoone in the 1st quarter valued at $1,539,000. Finally, Sei Investments Co. purchased a new stake in Billiontoone in the 1st quarter worth $1,058,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.